Trial Profile

Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra) Versus Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel) in Subjects 11 to 55 Years of Age in South Korea

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DTaP vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
Indications Diphtheria; Meningococcal infections; Pertussis; Tetanus
Focus Pharmacodynamics; Registrational
Sponsors Sanofi Pasteur

18 Jul 2013 Planned End Date changed from 1 Nov 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com